683240-76-8

Basic information

• Product Name: 5-BROMO-2-CHLORO-1H-BENZIMIDAZOLE
• Synonyms: 5-BROMO-2-CHLORO-1H-BENZIMIDAZOLE;5-BroMo-2-chloro-1H-benzo[d]iMidazole;6-Bromo-2-chloro-1H-benzoimidazole;5-Bromo-2-chlorobenzimidazole
• CAS NO: 683240-76-8
• Molecular Formula: C₇H₄BrClN₂
• Molecular Weight: 231.49
• Mol File: 683240-76-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 212-213°
• Boiling Point: 387.32 °C at 760 mmHg
• Flash Point: 188.044 °C
• Appearance: /
• Density: 1.878
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.73
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.56±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2-CHLORO-1H-BENZIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-CHLORO-1H-BENZIMIDAZOLE(683240-76-8)
• EPA Substance Registry System: 5-BROMO-2-CHLORO-1H-BENZIMIDAZOLE(683240-76-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 683240-76-8(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-chloro-1H-benzimidazole is a chemical compound with the molecular formula C7H4BrClN2. It is a heterocyclic aromatic compound containing a benzene ring fused to an imidazole ring with bromine and chlorine substituents attached to the benzene ring. 5-Bromo-2-chloro-1H-benzimidazole has been studied for its potential pharmaceutical applications, particularly as a potential anti-cancer agent. It is also used as a building block in the synthesis of various pharmaceuticals and agrochemicals. 5-Bromo-2-chloro-1H-benzimidazole is considered to be stable under normal temperature and pressure, but should be handled with caution due to its potential to cause skin and eye irritation.

InChI:InChI=1/C7H4BrClN2/c8-4-1-2-5-6(3-4)11-7(9)10-5/h1-3H,(H,10,11)

Upstream product

• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 39513-26-3 5-bromo-1,3-dihydro-benzoimidazol-2-one 
• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 4857-06-1 2-chloro-1H-benzoimidazole 

Downstream Products

• 1073558-66-3 8-(5-bromo-1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one 
• 808127-74-4 5-bromo-N-phenyl-1H-benzo[d]imidazol-2-amine 
• 1073558-70-9 8-[5-(4-fluorophenyl)-1H-benzimidazol-2-yl]-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one 
• 54303-63-8 C₇H₇BrN₄ 
• 1453097-58-9 C₁₈H₁₅BrN₄O 
• 1416334-91-2 2,4-difluoro-N-[2-(methyloxy)-5-(2-{[2-(4-morpholinyl)ethyl]amino}-1H-benzimidazol-5-yl)-3-pyridinyl]benzenesulfonamide 
• 1416334-92-3 2,4-difluoro-N-[2-(methyloxy)-5-(2-{[2-(1-pyrrolidinyl)ethyl]amino}-1H-benzimidazol-5-yl)-3-pyridinyl]benzenesulfonamide 
• 1359858-97-1 C₁₇H₁₆BrN₃O 

Relevant articles and documents

A α 7 smoke alkali acetylcholine receptor ligand and its preparation method

The present invention relates to an alpha7 nicotinic acetylcholine receptor ligand and a preparation method thereof. The ligand includes an agonist and an imaging agent, the agonist is a 1,4-diazabicyclo [3.2.2] nonane-benzo heterocyclic derivative, and the imaging agent is 125I and 18F-trifluoromethyl marker. The derivatives both have good brain uptake, the absorption values in different regions of the brain are basally consistent with the distribution of alpha7nAChR receptors, the uptake of the derives is highest in hippocampus, thalamus, cortex and other regions where the alpha7nAChR receptors targetedly distribute, and the derives can be blocked by known alpha7nAChR ligands but can not be blocked by alpha4beta2 medicine. Therefore, the 1,4-diazabicyclo [3.2.2] nonane-benzo heterocyclic derivative and the 125I and 18F-trifluoromethyl marker are potential agonist and imaging agent for alpha7 nicotinic acetylcholine receptors.

2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, -NH2, -NHR6, -NR7R8 and -NH-(R9)n-R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, -NH2, -NHR6, - NR7R8 and -NH-(R9)n-R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, -NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, -C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of -NH2, -N(R12)(V)pR13, - NH(V)p-OR14, -NHC(O)R15, and groups of formula la shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright